Clinical Trial Update: Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of MBG453 alone and with PDR001 in advanced malignancies; trial terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignancies

Drugs mentioned

• MBG453
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Malignancies | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-12-06